Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.82
- Piotroski Score 1.00
- Grade Buy
- Symbol (IMV)
- Company IMV Inc.
- Price $0.82
- Changes Percentage (0%)
- Change -$0
- Day Low $0.78
- Day High $0.84
- Year High $10.40
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/09/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.55
- Trailing P/E Ratio -0.18076923076923
- Forward P/E Ratio -0.18076923076923
- P/E Growth -0.18076923076923
- Net Income $-38,492,000
Income Statement
Quarterly
Annual
Latest News of IMV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?
Immunovant's fair value estimate is 19% higher than its analyst price target. Using a Discounted Cash Flow model, the intrinsic value of the company is calculated at US$8.5b, showing a 46% discount to...
By Yahoo! Finance | 4 weeks ago -
ZimVie Inc. (ZIMV) Stock Price, News, Quote & History - Yahoo Finance
ZimVie Inc. and its subsidiaries focus on developing and marketing products for treating spine pathologies and dental procedures globally. With two segments, Dental and Spine, they offer a range of de...
By Yahoo! Finance | 2 months ago
